ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber Sells 17,238 Shares

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 17,238 shares of ProKidney stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $2.50, for a total value of $43,095.00. Following the transaction, the senior vice president now owns 172,432 shares of the company’s stock, valued at approximately $431,080. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ProKidney Stock Performance

Shares of PROK stock traded up $0.12 during mid-day trading on Wednesday, hitting $2.84. The company’s stock had a trading volume of 3,434,136 shares, compared to its average volume of 641,363. ProKidney Corp. has a 52-week low of $1.12 and a 52-week high of $13.51. The business has a 50-day moving average price of $1.56 and a 200 day moving average price of $1.80. The stock has a market cap of $651.33 million, a price-to-earnings ratio of -4.98 and a beta of 1.08.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Equities research analysts predict that ProKidney Corp. will post -0.65 EPS for the current fiscal year.

Institutional Trading of ProKidney

Hedge funds have recently bought and sold shares of the company. Jump Financial LLC purchased a new stake in ProKidney during the third quarter valued at $216,000. SG Americas Securities LLC purchased a new stake in ProKidney during the third quarter valued at $78,000. Trexquant Investment LP purchased a new stake in ProKidney during the third quarter valued at $116,000. Barclays PLC increased its position in ProKidney by 355.2% during the fourth quarter. Barclays PLC now owns 61,815 shares of the company’s stock valued at $110,000 after acquiring an additional 48,234 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in ProKidney by 530.3% during the second quarter. Royal Bank of Canada now owns 6,965 shares of the company’s stock valued at $78,000 after purchasing an additional 5,860 shares during the period. Hedge funds and other institutional investors own 51.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PROK. Bank of America cut ProKidney from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Morgan Stanley began coverage on ProKidney in a research note on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price target for the company.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.